Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)

Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).

Placebo intravenous infusion with dosing volume equivalent to active treatment.